Anti-Infective Agents - Global Market Outlook (2016-2022)

Anti-Infective Agents - Global Market Outlook (2016-2022)

  • Published: October 2016
  • ID: SMRC15980

According to Stratistics MRC, the Global Anti Infective Agents Market is accounted for $83.8 billion in 2015 and expected to grow at a CAGR of 3.2% to reach $104.5 billion by 2022. Rising incidences of infectious diseases such as HIV, H1N1, and Ebola virus, awareness amongst the healthcare professionals and the patients and commercialization of pipeline products are boosting the market growth. Trends like treatment rates for communicable diseases in developing countries and treatment of Community Acquired Bacterial Pneumonia (CABP) are expected to impart the market growth. Growing resistance of infection to the drug therapies, high price of drugs, competition between generic manufacturers and perilous reimbursement policies will impede market growth.

The antibacterial segment accounted for the largest share of revenue. The anti-viral agents segment is expected to grow during the forecast period. North America commanded the anti-infective agents market and is followed by Europe. Asia Pacific is the fastest growing market due to improvements in healthcare infrastructure, demand for drugs and ongoing government initiatiatives for various control programs and strategic partnership projects.

Some of the key players in global Anti-Infective Agents market are AstraZeneca Plc, Boehringer Ingelheim, Bristol-Myers Squibb Co, Abbott Laboratories, Bayer Healthcare AG, Cipla Ltd, Gilead Sciences,Claris Life Sciences Ltd, GlaxoSmithKline Pharmaceuticals Ltd, Merck & Co., Inc, Novartis AG, Glenmark Pharmaceuticals Ltd, Lupin Ltd, Panacea Biotech Ltd, Pfizer Ltd, Ranbaxy Laboratories Ltd, Sun Pharmaceutical Industries Ltd., Johnson & Johnson Inc., Sanofi Aventis S.A., Beijing Double-Crane Pharmaceutical Co., Ltd, Anhui Jingfang Medical Industry Co.,Ltd and Hoffman-La Roche, Inc.  

Products Covered:
• Antibacterial agents
o Cephalosporins
o Carbapenems
o Fluoroquinolones
o Macrolides
o Penicillins
o Clindamycin
o B-Lactam Antibiotics
o Oxazolidinones
o Aminoglycosides
o Quinolones
o Sulfonamides
o Tetracyclines
o Vancomycin
• Antifungal agents
o Azoles 
o Echinocandins
o Polyenes
o Allylamines
o Macrolides derivatives
o Cresemba
• Antiviral agents
o DNA Polymerase Inhibitors
o Nucleoside Analogs
o Non-structural protein 5A (NS5A) inhibitors  
o Non-nucleoside reverse transcriptase inhibitors (NNRTIs)  
o Protease Inhibitors  
o Transcriptase Inhibitors  
o Neuraminidase inhibitors  
o Integrase strand transfer inhibitor  
o Chemokine receptor antagonist
• Antituberculosis agents
o Aminosalicylates 
o Diarylquinolines 
o Hydrazide derivatives 
o Nicotinic acid derivatives 
o Rifamycin derivatives 
o Streptomyces derivatives
• Vaccines
o Live/attenuated Vaccines  
o Inactivated Vaccines  
o DNA & Recombinant vector Vaccines  
o Toxoid vaccines
• Antitreponemal agents

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o France
o Italy
o UK 
o Spain     
o Rest of Europe 
• Asia Pacific
o Japan       
o China       
o India       
o Australia       
o New Zealand      
o Rest of Asia Pacific      
• Rest of the World
o Middle East
o Brazil
o Argentina
o South Africa
o Egypt

What our report offers:
- Market share assessments for the regional and country level segments
- Market share analysis of the top industry players
- Strategic recommendations for the new entrants
- Market forecasts for a minimum of 7 years of all the mentioned segments, sub segments and the regional markets
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements

1 Executive Summary      
        
2 Preface 
      
 2.1 Abstract      
 2.2 Stake Holders     
 2.3 Research Scope     
 2.4 Research Methodology    
  2.4.1 Data Mining    
  2.4.2 Data Analysis    
  2.4.3 Data Validation    
  2.4.4 Research Approach    
 2.5 Research Sources     
  2.5.1 Primary Research Sources   
  2.5.2 Secondary Research Sources   
  2.5.3 Assumptions    
        
3 Market Trend Analysis     
 3.1 Introduction     
 3.2 Drivers      
 3.3 Restraints     
 3.4 Opportunities     
 3.5 Threats      
 3.6 Emerging markets     
 3.7 Product Analysis     
        
4 Porters Five Force Analysis  
    
 4.1 Bargaining power of suppliers     
 4.2 Bargaining power of buyers       
 4.3 Threat of substitutes     
 4.4 Threat of new entrants        
 4.5 Competitive rivalry      
                              
5 Global Anti-Infective Agents Market, By Product   
 5.1 Introduction     
 5.2 Antibacterial agents     
  5.2.1 Cephalosporins    
  5.2.2 Carbapenems    
  5.2.3 Fluoroquinolones    
  5.2.4 Macrolides     
   5.2.4.1 Azithromycin   
   5.2.4.2 Clarithromycin XL   
   5.2.4.3 Erythromycin   
   5.2.4.4 Sulfisoxazole   
  5.2.5 Penicillins     
   5.2.5.1 Aminopenicillins   
   5.2.5.2 Antipseudomonal penicillins  
   5.2.5.3 Beta-lactamase inhibitors  
   5.2.5.4 Natural penicillins   
   5.2.5.5 Penicillinase resistant penicillins 
  5.2.6 Clindamycin    
  5.2.7 B-Lactam Antibiotics   
  5.2.8 Oxazolidinones    
  5.2.9 Aminoglycosides    
  5.2.10 Quinolones    
  5.2.11 Sulfonamides    
  5.2.12 Tetracyclines    
  5.2.13 Vancomycin    
 5.3 Antifungal agents      
  5.3.1 Azoles      
   5.3.1.1 Posaconazole   
   5.3.1.2 Clotrimazole   
   5.3.1.3 Fluconazole   
   5.3.1.4 Itraconazole   
   5.3.1.5 Ketoconazole   
   5.3.1.6 Voriconazole   
  5.3.2 Echinocandins     
  5.3.3 Polyenes     
  5.3.4 Allylamines    
  5.3.5 Macrolides derivatives   
  5.3.6 Cresemba    
 5.4 Antiviral agents      
  5.4.1 DNA Polymerase Inhibitors   
  5.4.2 Nucleoside Analogs    
   5.4.2.1 Pyrimidine Nucleosides  
   5.4.2.2 Purine Nucleosides   
  5.4.3 Non-structural protein 5A (NS5A) inhibitors 
  5.4.4 Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
  5.4.5 Protease Inhibitors    
  5.4.6 Transcriptase Inhibitors   
  5.4.7 Neuraminidase inhibitors   
  5.4.8 Integrase strand transfer inhibitor  
  5.4.9 Chemokine receptor antagonist  
 5.6 Antituberculosis agents    
  5.6.1 Aminosalicylates    
  5.6.2 Diarylquinolines    
  5.6.3 Hydrazide derivatives   
  5.6.4 Nicotinic acid derivatives   
  5.6.5 Rifamycin derivatives   
  5.6.6 Streptomyces derivatives   
 5.7 Vaccines      
  5.7.1 Live/attenuated Vaccines   
  5.7.2 Inactivated Vaccines   
  5.7.3 DNA & Recombinant vector Vaccines  
  5.7.4 Toxoid vaccines    
 5.8 Antitreponemal agents    
        
6 Global Anti-Infective Agents Market, By Geography   
 6.1 North America     
  6.1.1 US     
  6.1.2 Canada     
  6.1.3 Mexico     
 6.2 Europe      
  6.2.1 Germany     
  6.2.2 France     
  6.2.3 Italy     
  6.2.4 UK     
  6.2.5 Spain     
  6.2.6 Rest of Europe    
 6.3 Asia Pacific     
  6.3.1 Japan     
  6.3.2 China     
  6.3.3 India     
  6.3.4 Australia     
  6.3.5 New Zealand    
  6.3.6 Rest of Asia Pacific    
 6.4 Rest of the World     
  6.4.1 Middle East    
  6.4.2 Brazil     
  6.4.3 Argentina    
  6.4.4 South Africa    
  6.4.5 Egypt     
        
7  Key Developments      
 7.1 Agreements, Partnerships, Collaborations and Joint Ventures 
 7.2 Acquisitions & Mergers         
 7.3 New Product Launch    
 7.4 Expansions          
 7.5 Other Key Strategies     
        
8 Company Profiling      
 8.1 AstraZeneca Plc     
 8.2 Boehringer Ingelheim    
 8.3 Bristol-Myers Squibb Co    
 8.4 Abbott Laboratories     
 8.5 Bayer Healthcare AG    
 8.6 Cipla Ltd      
 8.7 Gilead Sciences     
 8.8 Claris Life Sciences Ltd    
 8.9 GlaxoSmithKline Pharmaceuticals Ltd   
 8.10 Merck & Co., Inc     
 8.11 Novartis AG     
 8.12 Glenmark Pharmaceuticals Ltd    
 8.13 Lupin Ltd      
 8.14 Panacea Biotech Ltd     
 8.15 Pfizer Ltd      
 8.16 Ranbaxy Laboratories Ltd    
 8.17 Sun Pharmaceutical Industries Ltd.   
 8.18 Johnson & Johnson Inc.    
 8.19 Sanofi Aventis S.A.     
 8.20 Beijing Double-Crane Pharmaceutical Co., Ltd  
 8.21 Anhui Jingfang Medical Industry Co.,Ltd   
 8.22 Hoffman-La Roche, Inc    


List of Tables                      
1 Global Anti-Infective Agents Market Analysis, by Region, (2013-2022) ($MN)
2 Global Anti-Infective Agents Market Analysis, by Product, (2013-2022) ($MN)
3 Global Anti-Infective Agents Market Analysis, by Antibacterial agents, (2013-2022) ($MN)
4 Global Anti-Infective Agents Market Analysis, by Cephalosporins, (2013-2022) ($MN)
5 Global Anti-Infective Agents Market Analysis, by Carbapenems, (2013-2022) ($MN)
6 Global Anti-Infective Agents Market Analysis, by Fluoroquinolones, (2013-2022) ($MN)
7 Global Anti-Infective Agents Market Analysis, by Macrolides, (2013-2022) ($MN)
8 Global Anti-Infective Agents Market Analysis, by Penicillins, (2013-2022) ($MN)
9 Global Anti-Infective Agents Market Analysis, by Clindamycin, (2013-2022) ($MN)
10 Global Anti-Infective Agents Market Analysis, by B-Lactam Antibiotics, (2013-2022) ($MN)
11 Global Anti-Infective Agents Market Analysis, by Oxazolidinones, (2013-2022) ($MN)
12 Global Anti-Infective Agents Market Analysis, by Aminoglycosides, (2013-2022) ($MN)
13 Global Anti-Infective Agents Market Analysis, by Quinolones, (2013-2022) ($MN)
14 Global Anti-Infective Agents Market Analysis, by Sulfonamides, (2013-2022) ($MN)
15 Global Anti-Infective Agents Market Analysis, by Tetracyclines, (2013-2022) ($MN)
16 Global Anti-Infective Agents Market Analysis, by Vancomycin, (2013-2022) ($MN)
17 Global Anti-Infective Agents Market Analysis, by Antifungal agents, (2013-2022) ($MN)
18 Global Anti-Infective Agents Market Analysis, by Azoles, (2013-2022) ($MN)
19 Global Anti-Infective Agents Market Analysis, by Echinocandins, (2013-2022) ($MN)
20 Global Anti-Infective Agents Market Analysis, by Polyenes, (2013-2022) ($MN)
21 Global Anti-Infective Agents Market Analysis, by Allylamines, (2013-2022) ($MN)
22 Global Anti-Infective Agents Market Analysis, by Macrolides derivatives, (2013-2022) ($MN)
23 Global Anti-Infective Agents Market Analysis, by Cresemba, (2013-2022) ($MN)
24 Global Anti-Infective Agents Market Analysis, by Antiviral agents, (2013-2022) ($MN)
25 Global Anti-Infective Agents Market Analysis, by DNA Polymerase Inhibitors, (2013-2022) ($MN)
26 Global Anti-Infective Agents Market Analysis, by Nucleoside Analogs, (2013-2022) ($MN)
27 Global Anti-Infective Agents Market Analysis, by Non-structural protein 5A (NS5A) inhibitors, (2013-2022) ($MN)
28 Global Anti-Infective Agents Market Analysis, by Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2013-2022) ($MN)
29 Global Anti-Infective Agents Market Analysis, by Protease Inhibitors, (2013-2022) ($MN)
30 Global Anti-Infective Agents Market Analysis, by Transcriptase Inhibitors, (2013-2022) ($MN)
31 Global Anti-Infective Agents Market Analysis, by Neuraminidase inhibitors, (2013-2022) ($MN)
32 Global Anti-Infective Agents Market Analysis, by Integrase strand transfer inhibitor, (2013-2022) ($MN)
33 Global Anti-Infective Agents Market Analysis, by Chemokine receptor antagonist, (2013-2022) ($MN)
34 Global Anti-Infective Agents Market Analysis, by Antituberculosis agents, (2013-2022) ($MN)
35 Global Anti-Infective Agents Market Analysis, by Aminosalicylates, (2013-2022) ($MN)
36 Global Anti-Infective Agents Market Analysis, by Diarylquinolines, (2013-2022) ($MN)
37 Global Anti-Infective Agents Market Analysis, by Hydrazide derivatives, (2013-2022) ($MN)
38 Global Anti-Infective Agents Market Analysis, by Nicotinic acid derivatives, (2013-2022) ($MN)
39 Global Anti-Infective Agents Market Analysis, by Rifamycin derivatives, (2013-2022) ($MN)
40 Global Anti-Infective Agents Market Analysis, by Streptomyces derivatives, (2013-2022) ($MN)
41 Global Anti-Infective Agents Market Analysis, by Vaccines, (2013-2022) ($MN)
42 Global Anti-Infective Agents Market Analysis, by Live/attenuated Vaccines, (2013-2022) ($MN)
43 Global Anti-Infective Agents Market Analysis, by Inactivated Vaccines, (2013-2022) ($MN)
44 Global Anti-Infective Agents Market Analysis, by DNA & Recombinant vector Vaccines, (2013-2022) ($MN)
45 Global Anti-Infective Agents Market Analysis, by Toxoid vaccines, (2013-2022) ($MN)
46 Global Anti-Infective Agents Market Analysis, by Antitreponemal agents, (2013-2022) ($MN)
47 North America Anti-Infective Agents Market Analysis, by Country, (2013-2022) ($MN)
48 North America Anti-Infective Agents Market Analysis, by Product, (2013-2022) ($MN)
49 North America Anti-Infective Agents Market Analysis, by Antibacterial agents, (2013-2022) ($MN)
50 North America Anti-Infective Agents Market Analysis, by Cephalosporins, (2013-2022) ($MN)
51 North America Anti-Infective Agents Market Analysis, by Carbapenems, (2013-2022) ($MN)
52 North America Anti-Infective Agents Market Analysis, by Fluoroquinolones, (2013-2022) ($MN)
53 North America Anti-Infective Agents Market Analysis, by Macrolides, (2013-2022) ($MN)
54 North America Anti-Infective Agents Market Analysis, by Penicillins, (2013-2022) ($MN)
55 North America Anti-Infective Agents Market Analysis, by Clindamycin, (2013-2022) ($MN)
56 North America Anti-Infective Agents Market Analysis, by B-Lactam Antibiotics, (2013-2022) ($MN)
57 North America Anti-Infective Agents Market Analysis, by Oxazolidinones, (2013-2022) ($MN)
58 North America Anti-Infective Agents Market Analysis, by Aminoglycosides, (2013-2022) ($MN)
59 North America Anti-Infective Agents Market Analysis, by Quinolones, (2013-2022) ($MN)
60 North America Anti-Infective Agents Market Analysis, by Sulfonamides, (2013-2022) ($MN)
61 North America Anti-Infective Agents Market Analysis, by Tetracyclines, (2013-2022) ($MN)
62 North America Anti-Infective Agents Market Analysis, by Vancomycin, (2013-2022) ($MN)
63 North America Anti-Infective Agents Market Analysis, by Antifungal agents, (2013-2022) ($MN)
64 North America Anti-Infective Agents Market Analysis, by Azoles, (2013-2022) ($MN)
65 North America Anti-Infective Agents Market Analysis, by Echinocandins, (2013-2022) ($MN)
66 North America Anti-Infective Agents Market Analysis, by Polyenes, (2013-2022) ($MN)
67 North America Anti-Infective Agents Market Analysis, by Allylamines, (2013-2022) ($MN)
68 North America Anti-Infective Agents Market Analysis, by Macrolides derivatives, (2013-2022) ($MN)
69 North America Anti-Infective Agents Market Analysis, by Cresemba, (2013-2022) ($MN)
70 North America Anti-Infective Agents Market Analysis, by Antiviral agents, (2013-2022) ($MN)
71 North America Anti-Infective Agents Market Analysis, by DNA Polymerase Inhibitors, (2013-2022) ($MN)
72 North America Anti-Infective Agents Market Analysis, by Nucleoside Analogs, (2013-2022) ($MN)
73 North America Anti-Infective Agents Market Analysis, by Non-structural protein 5A (NS5A) inhibitors, (2013-2022) ($MN)
74 North America Anti-Infective Agents Market Analysis, by Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2013-2022) ($MN)
75 North America Anti-Infective Agents Market Analysis, by Protease Inhibitors, (2013-2022) ($MN)
76 North America Anti-Infective Agents Market Analysis, by Transcriptase Inhibitors, (2013-2022) ($MN)
77 North America Anti-Infective Agents Market Analysis, by Neuraminidase inhibitors, (2013-2022) ($MN)
78 North America Anti-Infective Agents Market Analysis, by Integrase strand transfer inhibitor, (2013-2022) ($MN)
79 North America Anti-Infective Agents Market Analysis, by Chemokine receptor antagonist, (2013-2022) ($MN)
80 North America Anti-Infective Agents Market Analysis, by Antituberculosis agents, (2013-2022) ($MN)
81 North America Anti-Infective Agents Market Analysis, by Aminosalicylates, (2013-2022) ($MN)
82 North America Anti-Infective Agents Market Analysis, by Diarylquinolines, (2013-2022) ($MN)
83 North America Anti-Infective Agents Market Analysis, by Hydrazide derivatives, (2013-2022) ($MN)
84 North America Anti-Infective Agents Market Analysis, by Nicotinic acid derivatives, (2013-2022) ($MN)
85 North America Anti-Infective Agents Market Analysis, by Rifamycin derivatives, (2013-2022) ($MN)
86 North America Anti-Infective Agents Market Analysis, by Streptomyces derivatives, (2013-2022) ($MN)
87 North America Anti-Infective Agents Market Analysis, by Vaccines, (2013-2022) ($MN)
88 North America Anti-Infective Agents Market Analysis, by Live/attenuated Vaccines, (2013-2022) ($MN)
89 North America Anti-Infective Agents Market Analysis, by Inactivated Vaccines, (2013-2022) ($MN)
90 North America Anti-Infective Agents Market Analysis, by DNA & Recombinant vector Vaccines, (2013-2022) ($MN)
91 North America Anti-Infective Agents Market Analysis, by Toxoid vaccines, (2013-2022) ($MN)
92 North America Anti-Infective Agents Market Analysis, by Antitreponemal agents, (2013-2022) ($MN)
93 Europe Anti-Infective Agents Market Analysis, by Country, (2013-2022) ($MN)
94 Europe Anti-Infective Agents Market Analysis, by Product, (2013-2022) ($MN)
95 Europe Anti-Infective Agents Market Analysis, by Antibacterial agents, (2013-2022) ($MN)
96 Europe Anti-Infective Agents Market Analysis, by Cephalosporins, (2013-2022) ($MN)
97 Europe Anti-Infective Agents Market Analysis, by Carbapenems, (2013-2022) ($MN)
98 Europe Anti-Infective Agents Market Analysis, by Fluoroquinolones, (2013-2022) ($MN)
99 Europe Anti-Infective Agents Market Analysis, by Macrolides, (2013-2022) ($MN)
100 Europe Anti-Infective Agents Market Analysis, by Penicillins, (2013-2022) ($MN)
101 Europe Anti-Infective Agents Market Analysis, by Clindamycin, (2013-2022) ($MN)
102 Europe Anti-Infective Agents Market Analysis, by B-Lactam Antibiotics, (2013-2022) ($MN)
103 Europe Anti-Infective Agents Market Analysis, by Oxazolidinones, (2013-2022) ($MN)
104 Europe Anti-Infective Agents Market Analysis, by Aminoglycosides, (2013-2022) ($MN)
105 Europe Anti-Infective Agents Market Analysis, by Quinolones, (2013-2022) ($MN)
106 Europe Anti-Infective Agents Market Analysis, by Sulfonamides, (2013-2022) ($MN)
107 Europe Anti-Infective Agents Market Analysis, by Tetracyclines, (2013-2022) ($MN)
108 Europe Anti-Infective Agents Market Analysis, by Vancomycin, (2013-2022) ($MN)
109 Europe Anti-Infective Agents Market Analysis, by Antifungal agents, (2013-2022) ($MN)
110 Europe Anti-Infective Agents Market Analysis, by Azoles, (2013-2022) ($MN)
111 Europe Anti-Infective Agents Market Analysis, by Echinocandins, (2013-2022) ($MN)
112 Europe Anti-Infective Agents Market Analysis, by Polyenes, (2013-2022) ($MN)
113 Europe Anti-Infective Agents Market Analysis, by Allylamines, (2013-2022) ($MN)
114 Europe Anti-Infective Agents Market Analysis, by Macrolides derivatives, (2013-2022) ($MN)
115 Europe Anti-Infective Agents Market Analysis, by Cresemba, (2013-2022) ($MN)
116 Europe Anti-Infective Agents Market Analysis, by Antiviral agents, (2013-2022) ($MN)
117 Europe Anti-Infective Agents Market Analysis, by DNA Polymerase Inhibitors, (2013-2022) ($MN)
118 Europe Anti-Infective Agents Market Analysis, by Nucleoside Analogs, (2013-2022) ($MN)
119 Europe Anti-Infective Agents Market Analysis, by Non-structural protein 5A (NS5A) inhibitors, (2013-2022) ($MN)
120 Europe Anti-Infective Agents Market Analysis, by Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2013-2022) ($MN)
121 Europe Anti-Infective Agents Market Analysis, by Protease Inhibitors, (2013-2022) ($MN)
122 Europe Anti-Infective Agents Market Analysis, by Transcriptase Inhibitors, (2013-2022) ($MN)
123 Europe Anti-Infective Agents Market Analysis, by Neuraminidase inhibitors, (2013-2022) ($MN)
124 Europe Anti-Infective Agents Market Analysis, by Integrase strand transfer inhibitor, (2013-2022) ($MN)
125 Europe Anti-Infective Agents Market Analysis, by Chemokine receptor antagonist, (2013-2022) ($MN)
126 Europe Anti-Infective Agents Market Analysis, by Antituberculosis agents, (2013-2022) ($MN)
127 Europe Anti-Infective Agents Market Analysis, by Aminosalicylates, (2013-2022) ($MN)
128 Europe Anti-Infective Agents Market Analysis, by Diarylquinolines, (2013-2022) ($MN)
129 Europe Anti-Infective Agents Market Analysis, by Hydrazide derivatives, (2013-2022) ($MN)
130 Europe Anti-Infective Agents Market Analysis, by Nicotinic acid derivatives, (2013-2022) ($MN)
131 Europe Anti-Infective Agents Market Analysis, by Rifamycin derivatives, (2013-2022) ($MN)
132 Europe Anti-Infective Agents Market Analysis, by Streptomyces derivatives, (2013-2022) ($MN)
133 Europe Anti-Infective Agents Market Analysis, by Vaccines, (2013-2022) ($MN)
134 Europe Anti-Infective Agents Market Analysis, by Live/attenuated Vaccines, (2013-2022) ($MN)
135 Europe Anti-Infective Agents Market Analysis, by Inactivated Vaccines, (2013-2022) ($MN)
136 Europe Anti-Infective Agents Market Analysis, by DNA & Recombinant vector Vaccines, (2013-2022) ($MN)
137 Europe Anti-Infective Agents Market Analysis, by Toxoid vaccines, (2013-2022) ($MN)
138 Europe Anti-Infective Agents Market Analysis, by Antitreponemal agents, (2013-2022) ($MN)
139 Asia Pacific Anti-Infective Agents Market Analysis, by Country, (2013-2022) ($MN)
140 Asia Pacific Anti-Infective Agents Market Analysis, by Product, (2013-2022) ($MN)
141 Asia Pacific Anti-Infective Agents Market Analysis, by Antibacterial agents, (2013-2022) ($MN)
142 Asia Pacific Anti-Infective Agents Market Analysis, by Cephalosporins, (2013-2022) ($MN)
143 Asia Pacific Anti-Infective Agents Market Analysis, by Carbapenems, (2013-2022) ($MN)
144 Asia Pacific Anti-Infective Agents Market Analysis, by Fluoroquinolones, (2013-2022) ($MN)
145 Asia Pacific Anti-Infective Agents Market Analysis, by Macrolides, (2013-2022) ($MN)
146 Asia Pacific Anti-Infective Agents Market Analysis, by Penicillins, (2013-2022) ($MN)
147 Asia Pacific Anti-Infective Agents Market Analysis, by Clindamycin, (2013-2022) ($MN)
148 Asia Pacific Anti-Infective Agents Market Analysis, by B-Lactam Antibiotics, (2013-2022) ($MN)
149 Asia Pacific Anti-Infective Agents Market Analysis, by Oxazolidinones, (2013-2022) ($MN)
150 Asia Pacific Anti-Infective Agents Market Analysis, by Aminoglycosides, (2013-2022) ($MN)
151 Asia Pacific Anti-Infective Agents Market Analysis, by Quinolones, (2013-2022) ($MN)
152 Asia Pacific Anti-Infective Agents Market Analysis, by Sulfonamides, (2013-2022) ($MN)
153 Asia Pacific Anti-Infective Agents Market Analysis, by Tetracyclines, (2013-2022) ($MN)
154 Asia Pacific Anti-Infective Agents Market Analysis, by Vancomycin, (2013-2022) ($MN)
155 Asia Pacific Anti-Infective Agents Market Analysis, by Antifungal agents, (2013-2022) ($MN)
156 Asia Pacific Anti-Infective Agents Market Analysis, by Azoles, (2013-2022) ($MN)
157 Asia Pacific Anti-Infective Agents Market Analysis, by Echinocandins, (2013-2022) ($MN)
158 Asia Pacific Anti-Infective Agents Market Analysis, by Polyenes, (2013-2022) ($MN)
159 Asia Pacific Anti-Infective Agents Market Analysis, by Allylamines, (2013-2022) ($MN)
160 Asia Pacific Anti-Infective Agents Market Analysis, by Macrolides derivatives, (2013-2022) ($MN)
161 Asia Pacific Anti-Infective Agents Market Analysis, by Cresemba, (2013-2022) ($MN)
162 Asia Pacific Anti-Infective Agents Market Analysis, by Antiviral agents, (2013-2022) ($MN)
163 Asia Pacific Anti-Infective Agents Market Analysis, by DNA Polymerase Inhibitors, (2013-2022) ($MN)
164 Asia Pacific Anti-Infective Agents Market Analysis, by Nucleoside Analogs, (2013-2022) ($MN)
165 Asia Pacific Anti-Infective Agents Market Analysis, by Non-structural protein 5A (NS5A) inhibitors, (2013-2022) ($MN)
166 Asia Pacific Anti-Infective Agents Market Analysis, by Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2013-2022) ($MN)
167 Asia Pacific Anti-Infective Agents Market Analysis, by Protease Inhibitors, (2013-2022) ($MN)
168 Asia Pacific Anti-Infective Agents Market Analysis, by Transcriptase Inhibitors, (2013-2022) ($MN)
169 Asia Pacific Anti-Infective Agents Market Analysis, by Neuraminidase inhibitors, (2013-2022) ($MN)
170 Asia Pacific Anti-Infective Agents Market Analysis, by Integrase strand transfer inhibitor, (2013-2022) ($MN)
171 Asia Pacific Anti-Infective Agents Market Analysis, by Chemokine receptor antagonist, (2013-2022) ($MN)
172 Asia Pacific Anti-Infective Agents Market Analysis, by Antituberculosis agents, (2013-2022) ($MN)
173 Asia Pacific Anti-Infective Agents Market Analysis, by Aminosalicylates, (2013-2022) ($MN)
174 Asia Pacific Anti-Infective Agents Market Analysis, by Diarylquinolines, (2013-2022) ($MN)
175 Asia Pacific Anti-Infective Agents Market Analysis, by Hydrazide derivatives, (2013-2022) ($MN)
176 Asia Pacific Anti-Infective Agents Market Analysis, by Nicotinic acid derivatives, (2013-2022) ($MN)
177 Asia Pacific Anti-Infective Agents Market Analysis, by Rifamycin derivatives, (2013-2022) ($MN)
178 Asia Pacific Anti-Infective Agents Market Analysis, by Streptomyces derivatives, (2013-2022) ($MN)
179 Asia Pacific Anti-Infective Agents Market Analysis, by Vaccines, (2013-2022) ($MN)
180 Asia Pacific Anti-Infective Agents Market Analysis, by Live/attenuated Vaccines, (2013-2022) ($MN)
181 Asia Pacific Anti-Infective Agents Market Analysis, by Inactivated Vaccines, (2013-2022) ($MN)
182 Asia Pacific Anti-Infective Agents Market Analysis, by DNA & Recombinant vector Vaccines, (2013-2022) ($MN)
183 Asia Pacific Anti-Infective Agents Market Analysis, by Toxoid vaccines, (2013-2022) ($MN)
184 Asia Pacific Anti-Infective Agents Market Analysis, by Antitreponemal agents, (2013-2022) ($MN)
185 RoW Anti-Infective Agents Market Analysis, by Country, (2013-2022) ($MN)
186 RoW Anti-Infective Agents Market Analysis, by Product, (2013-2022) ($MN)
187 RoW Anti-Infective Agents Market Analysis, by Antibacterial agents, (2013-2022) ($MN)
188 RoW Anti-Infective Agents Market Analysis, by Cephalosporins, (2013-2022) ($MN)
189 RoW Anti-Infective Agents Market Analysis, by Carbapenems, (2013-2022) ($MN)
190 RoW Anti-Infective Agents Market Analysis, by Fluoroquinolones, (2013-2022) ($MN)
191 RoW Anti-Infective Agents Market Analysis, by Macrolides, (2013-2022) ($MN)
192 RoW Anti-Infective Agents Market Analysis, by Penicillins, (2013-2022) ($MN)
193 RoW Anti-Infective Agents Market Analysis, by Clindamycin, (2013-2022) ($MN)
194 RoW Anti-Infective Agents Market Analysis, by B-Lactam Antibiotics, (2013-2022) ($MN)
195 RoW Anti-Infective Agents Market Analysis, by Oxazolidinones, (2013-2022) ($MN)
196 RoW Anti-Infective Agents Market Analysis, by Aminoglycosides, (2013-2022) ($MN)
197 RoW Anti-Infective Agents Market Analysis, by Quinolones, (2013-2022) ($MN)
198 RoW Anti-Infective Agents Market Analysis, by Sulfonamides, (2013-2022) ($MN)
199 RoW Anti-Infective Agents Market Analysis, by Tetracyclines, (2013-2022) ($MN)
200 RoW Anti-Infective Agents Market Analysis, by Vancomycin, (2013-2022) ($MN)
201 RoW Anti-Infective Agents Market Analysis, by Antifungal agents, (2013-2022) ($MN)
202 RoW Anti-Infective Agents Market Analysis, by Azoles, (2013-2022) ($MN)
203 RoW Anti-Infective Agents Market Analysis, by Echinocandins, (2013-2022) ($MN)
204 RoW Anti-Infective Agents Market Analysis, by Polyenes, (2013-2022) ($MN)
205 RoW Anti-Infective Agents Market Analysis, by Allylamines, (2013-2022) ($MN)
206 RoW Anti-Infective Agents Market Analysis, by Macrolides derivatives, (2013-2022) ($MN)
207 RoW Anti-Infective Agents Market Analysis, by Cresemba, (2013-2022) ($MN)
208 RoW Anti-Infective Agents Market Analysis, by Antiviral agents, (2013-2022) ($MN)
209 RoW Anti-Infective Agents Market Analysis, by DNA Polymerase Inhibitors, (2013-2022) ($MN)
210 RoW Anti-Infective Agents Market Analysis, by Nucleoside Analogs, (2013-2022) ($MN)
211 RoW Anti-Infective Agents Market Analysis, by Non-structural protein 5A (NS5A) inhibitors, (2013-2022) ($MN)
212 RoW Anti-Infective Agents Market Analysis, by Non-nucleoside reverse transcriptase inhibitors (NNRTIs), (2013-2022) ($MN)
213 RoW Anti-Infective Agents Market Analysis, by Protease Inhibitors, (2013-2022) ($MN)
214 RoW Anti-Infective Agents Market Analysis, by Transcriptase Inhibitors, (2013-2022) ($MN)
215 RoW Anti-Infective Agents Market Analysis, by Neuraminidase inhibitors, (2013-2022) ($MN)
216 RoW Anti-Infective Agents Market Analysis, by Integrase strand transfer inhibitor, (2013-2022) ($MN)
217 RoW Anti-Infective Agents Market Analysis, by Chemokine receptor antagonist, (2013-2022) ($MN)
218 RoW Anti-Infective Agents Market Analysis, by Antituberculosis agents, (2013-2022) ($MN)
219 RoW Anti-Infective Agents Market Analysis, by Aminosalicylates, (2013-2022) ($MN)
220 RoW Anti-Infective Agents Market Analysis, by Diarylquinolines, (2013-2022) ($MN)
221 RoW Anti-Infective Agents Market Analysis, by Hydrazide derivatives, (2013-2022) ($MN)
222 RoW Anti-Infective Agents Market Analysis, by Nicotinic acid derivatives, (2013-2022) ($MN)
223 RoW Anti-Infective Agents Market Analysis, by Rifamycin derivatives, (2013-2022) ($MN)
224 RoW Anti-Infective Agents Market Analysis, by Streptomyces derivatives, (2013-2022) ($MN)
225 RoW Anti-Infective Agents Market Analysis, by Vaccines, (2013-2022) ($MN)
226 RoW Anti-Infective Agents Market Analysis, by Live/attenuated Vaccines, (2013-2022) ($MN)
227 RoW Anti-Infective Agents Market Analysis, by Inactivated Vaccines, (2013-2022) ($MN)
228 RoW Anti-Infective Agents Market Analysis, by DNA & Recombinant vector Vaccines, (2013-2022) ($MN)
229 RoW Anti-Infective Agents Market Analysis, by Toxoid vaccines, (2013-2022) ($MN)
230 RoW Anti-Infective Agents Market Analysis, by Antitreponemal agents, (2013-2022) ($MN)

 

1. What do I do if I have a query on this report?
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
2. Is the sample available for this report? Can I request the sample with my specific requirements?
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
3. Format of the report?
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: [email protected] or phone: +1-301-202-5929
4. Services prior to purchase and after purchase?
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.
5. License Type and Delivery?
We have 3 different licensing options available in electronic format.
  • Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
  • 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
  • Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment
6. Purchase procedure and Invoicing?
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards
7. Post sale support?
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.

We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at [email protected] or call us on +1-301-202-5929.

Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.

Select License Type

Single User License (PDF)

 

2 - 5 User License (PDF)

 

Site License (PDF)

 

Corporate License (PDF)

 

Have a Question?


Know our Methodology

WHY CHOOSE US ?

Assured Quality

Best in class reports with high standard of research integrity

24X7 Research Support

Continuous support to ensure the best customer experience.

Free Customization

Adding more values to your product of interest.

Safe & Secure Access

Providing a secured environment for all online transactions.

Trusted by 600+ Brands

Serving the most reputed brands across the world.

Testimonials